Related Experiment Video

Updated: Aug 10, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

CDC7 kinase inhibitors: a survey of recent patent literature (2017-2022)

Takayuki Irie1, Masaaki Sawa1

  • 1Drug Discovery and Development, Carna Biosciences, Inc, Kobe, Japan.

Expert Opinion on Therapeutic Patents
|September 22, 2023
PubMed
Abstract

Insights

CDC7 kinase is a promising cancer drug target. Novel inhibitors are needed to improve efficacy and reduce toxicity, alongside patient stratification for better treatment outcomes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • CDC7 is a serine/threonine kinase crucial for DNA replication.
  • Inhibiting CDC7 kinase is lethal to cancer cells but arrests normal cells, marking it a potential therapeutic target.
  • Limited chemical scaffolds and clinical trial failures highlight the need for novel CDC7 inhibitors.

Purpose of the Study:

  • To review patent literature on novel small molecule compounds inhibiting CDC7 from 2017-2022.
  • To identify emerging chemical scaffolds for CDC7 inhibition.
  • To address challenges in clinical development, including toxicity and patient stratification.

Main Methods:

  • Comprehensive search of patent literature from 2017 to 2022.
  • Analysis of disclosed small molecule compounds targeting CDC7.
  • Review of clinical trial data and expert opinions on CDC7 inhibitors.

Main Results:

  • A limited number of chemical scaffolds for CDC7 inhibitors have been reported.
  • Several CDC7 inhibitors have entered clinical trials with suboptimal efficacy.
  • Dose-limiting toxicities and lack of patient stratification are key challenges.

Conclusions:

  • CDC7 remains a significant drug target for cancer therapy.
  • Development of novel chemical scaffolds is essential to overcome toxicity issues.
  • Patient stratification and biomarker identification are critical for successful CDC7 inhibitor development.
Keywords:
ALSCDC7DNA damage responseDNA replicationcancerkinase inhibitorsmitotic catastrophesmall molecule inhibitors

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...